FDA awards 9 companies priority review vouchers for expedited drug approvals
TL;DR Summary
The FDA has issued its first nine priority review vouchers to expedite the approval process for certain drugs and therapies, including Regeneron's gene therapy for hearing loss, with the aim of reducing approval times from 10-12 months to 1-2 months, focusing on public health priorities and affordability.
- FDA names 9 first recipients of 1- to 2-month priority review vouchers Fierce Biotech
- FDA unveils drugs to receive expedited review in support of ‘national priorities’ AP News
- US FDA announces recipients of national priority vouchers Reuters
- FDA awards 9 companies a new ‘national priority’ voucher to speed drug reviews BioPharma Dive
- FDA unveils nine drugs getting streamlined reviews Axios
Reading Insights
Total Reads
0
Unique Readers
0
Time Saved
3 min
vs 4 min read
Condensed
92%
620 → 47 words
Want the full story? Read the original article
Read on Fierce Biotech